Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B

MADRIGAL PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$14.47 revenue$14,638,000

Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.
Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.
EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.
Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.
Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.